Nurix Therapeutics Inc stock is traded at $14.84, with a volume of 7,091,384. It is down -6.96% in the last 24 hours and down -34.34% over the past month. Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Previous Close:
$15.95
Open:
$16.01
24h Volume:
7,091,384
Relative Volume:
1.51
Market Cap:
$1.62B
Revenue:
$71.78M
Net Income/Loss:
-$295.28M
P/E Ratio:
-
EPS:
-$3.16
Net Cash Flow:
-$271.85M
1W Performance:
-44.63%
1M Performance:
-34.34%
6M Performance:
-12.09%
1Y Performance:
+18.53%
1-Day Range:
$0.00$0.00
1-Week Range:
$14.78$26.96
52-Week Range:
$11.67$28.23
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(415) 660-5320Address
1600 SIERRA POINT PKWY, BRISBANE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS